Innovative Closed Process CAR-T
Cell Therapy Platform to Streamline Approach for Manufacturing with Great Predictability
Please join us for this free, live Ask the Expert webcast.Just fill out the form below to register.
Presenters:
Tatiana GolovinaSenior Director, Cell Therapy Process Development
WuXi Advanced Technologies
Tatiana Golovina is a process development lead with multidisciplinary experience extending from bioorganic chemistry to immunology and cell therapy with 20+ years of experience in early and late cell therapy process development, process characterization, scale-up and transfer, translational research, and product stewardship. Before joining WuXi, Tatiana worked at Novartis in Morris Plains/East Hanover, NJ, towards development and commercialization of Kymriah (tisagenlecleucel), the first commercially approved CAR T-cell therapy in the United States. Prior to Novartis, Tatiana was the Head of Assay Development at the Fraunhofer Center for Molecular Biotechnology, and she worked in the cell therapy field at the University of Pennsylvania and in the antigen presentation field at Thomas Jefferson University. She holds a PhD from the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry in Moscow, Russia.
